Cite
HARVARD Citation
Roviello, G. et al. (2018). Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer. Medicine. 97 (20), p. . [Online].